The Helsinki Court of Appeal found that ratiopharm had infringed Merck’s supplementary protection certificate covering losartan. The Court applied the reversed burden of proof of the Patents Act, which has its basis on Article 34 of the TRIPS Agreement. It further considered that, in the absence of proof to the contrary, the active ingredient losartan in ratiopharm’s Losatrix- and Losatrix Comp -products was deemed to have been produced using a manufacturing process within the scope of Merck’s patent.

A summary of this case will be posted on http://www.Kluweriplaw.com


_____________________________

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.


Kluwer IP Law